Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bavituximab - Avid Bioservices

Drug Profile

Bavituximab - Avid Bioservices

Alternative Names: 3G4; Anti-phosphatidylserine monoclonal antibody 3G4; Anti-phospholipid monoclonal antibody 3G4; Anti-PS MAb 3G4; Monoclonal antibody 3G4; Tarvacin

Latest Information Update: 02 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Avid Bioservices; University of Texas M. D. Anderson Cancer Center
  • Developer Avid Bioservices; IMV; Massachusetts General Hospital; Merck Sharp & Dohme; Peregrine Pharmaceuticals; University of Arizona; University of Texas Southwestern Medical Center
  • Class Adjuvants; Antineoplastics; Antivirals; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Antibody-dependent cell cytotoxicity; Phosphatidylserine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Glioblastoma; Liver cancer
  • Preclinical Solid tumours
  • Suspended Breast cancer; Malignant melanoma; Pancreatic cancer
  • No development reported Brain cancer; Hepatitis C; HIV infections; Rectal cancer; Viral haemorrhagic fevers
  • Discontinued Influenza virus infections; Prostate cancer

Most Recent Events

  • 15 Oct 2018 H. Lee Moffitt Cancer Center and Research Institute and National Comprehensive Cancer Network withdraws phase-I clinical trials in liver cancer (Combination therapy, Late-stage disease, Inoperable/Unresectable, First-line therapy) in USA (IV) prior to enrolment (NCT02989870)
  • 24 Jun 2018 Biomarkers information updated
  • 28 May 2018 No recent reports of development identified for phase-I development in Rectal cancer(Combination therapy, Late-stage disease) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top